Saul Centers, Inc. – Consensus Indicates Potential 17.9% Upside

DirectorsTalk Interviews

Saul Centers, Inc. found using ticker (BFS) now have 3 analysts in total covering the stock. The consensus rating is ‘Hold’. The target price ranges between 53 and 50 calculating the average target price we see 51. Now with the previous closing price of 43.24 this is indicating there is a potential upside of 17.9%. The 50 day MA is 48.01 and the 200 day moving average is 49.21. The company has a market capitalisation of $1,418m. You can visit the company’s website by visiting: https://www.saulcenters.com

The potential market cap would be $1,673m based on the market concensus.

Saul Centers, Inc. is a self-managed, self-administered equity REIT headquartered in Bethesda, Maryland, which currently operates and manages a real estate portfolio of 60 properties which includes (a) 50 community and neighborhood shopping centers and seven mixed-use properties with approximately 9.8 million square feet of leasable area and (b) three land and development properties. Approximately 85% of the Saul Centers’ property operating income is generated by properties in the metropolitan Washington, DC/Baltimore area.

Share on:
Find more news, interviews, share price & company profile here for:

    JPMorgan European Discovery Trust reports strong performance uplift in latest factsheet

    JPMorgan European Discovery Trust reported a 5.37% share price rise in July 2025, outpacing NAV and its benchmark. Year-to-date, the share price is up 34.17%, supported by strong small-cap performance and effective stock selection.

    Golden Matrix reports record August revenue of $17.8m, up 18% year-on-year

    Golden Matrix posted record August revenues of $17.8m, up 18% from last year, with July revenues also rising 24% to $15.7m. Strong performance came from Meridianbet’s sports betting and RKings’ tournaments, positioning the group for record Q3 results.

    HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

    HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World Conference on Lung Cancer in Barcelona and the CSCO Annual Meeting in China this September. Presentations include studies on savolitinib, surufatinib, fruquintinib and first-in-human results for HMPL-653.

    Surface Transforms appoints Paul Marr as Non-Executive Director

    Surface Transforms has appointed Paul Marr to its Board as Non-Executive Director. Marr brings over 40 years of global automotive manufacturing and operational leadership experience, including senior roles at General Motors and other international groups.

    Avation signs 12-year lease for ATR 72-600 with Cambodian airline

    Avation has agreed a twelve-year lease with a Cambodian carrier for a new ATR 72-600, the second of ten aircraft ordered in 2024. Delivery is scheduled for February 2026.

    Tern Plc delivers stronger interim results with reduced loss and portfolio growth

    Tern Plc reported improved interim results for the six months to 30 June 2025, with a 64% reduction in loss, disciplined cost control, and a new strategic investment in Sure Ventures plc. The company also strengthened portfolio support through successful fundraises.

      Search

      Search